These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 11132964)

  • 1. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
    Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
    J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.
    Tawara S; Ikeda F; Maki K; Morishita Y; Otomo K; Teratani N; Goto T; Tomishima M; Ohki H; Yamada A; Kawabata K; Takasugi H; Sakane K; Tanaka H; Matsumoto F; Kuwahara S
    Antimicrob Agents Chemother; 2000 Jan; 44(1):57-62. PubMed ID: 10602723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.
    Mikamo H; Sato Y; Tamaya T
    J Antimicrob Chemother; 2000 Sep; 46(3):485-7. PubMed ID: 10980180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.
    Ikeda F; Wakai Y; Matsumoto S; Maki K; Watabe E; Tawara S; Goto T; Watanabe Y; Matsumoto F; Kuwahara S
    Antimicrob Agents Chemother; 2000 Mar; 44(3):614-8. PubMed ID: 10681327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
    Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds.
    Nakai T; Uno J; Otomo K; Ikeda F; Tawara S; Goto T; Nishimura K; Miyaji M
    Chemotherapy; 2002 May; 48(2):78-81. PubMed ID: 12011539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro activity of a new semisynthetic echinocandin, micafungin, against clinical isolates of Candida species isolated in Tenri Hospital].
    Komatsu M; Aihara M; Shimakawa K; Iwasaki M; Nagasaka Y; Fukuda S; Abe N; Matsuo S
    Jpn J Antibiot; 2003 Dec; 56(6):705-11. PubMed ID: 15007879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
    Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
    J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
    Warn PA; Morrissey G; Morrissey J; Denning DW
    J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts.
    Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K
    Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of MICs of aminocandin for Candida spp. and filamentous fungi.
    Isham N; Ghannoum MA
    J Clin Microbiol; 2006 Dec; 44(12):4342-4. PubMed ID: 17021057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.
    Maesaki S; Hossain MA; Miyazaki Y; Tomono K; Tashiro T; Kohno S
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1728-30. PubMed ID: 10817741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antifungal susceptibility among the isolates of yeast from the University Hospital of the Ryukyus].
    Ohta C; Yamane N; Nakasone I; Onaga S; Nakamura K
    Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi; 2005; 16(2):127-33. PubMed ID: 16536058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds.
    Miyazaki M; Horii T; Hata K; Watanabe NA; Nakamoto K; Tanaka K; Shirotori S; Murai N; Inoue S; Matsukura M; Abe S; Yoshimatsu K; Asada M
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4652-8. PubMed ID: 21825291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Micafungin (FK463) on Candida albicans adherence to epithelial cells.
    Borg-von Zepelin M; Zaschke K; Gross U; Monod M; Müller FM
    Chemotherapy; 2002 Jul; 48(3):148-53. PubMed ID: 12138332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms.
    Nakai T; Uno J; Ikeda F; Tawara S; Nishimura K; Miyaji M
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1376-81. PubMed ID: 12654673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi.
    Herreros E; Martinez CM; Almela MJ; Marriott MS; De Las Heras FG; Gargallo-Viola D
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2863-9. PubMed ID: 9797217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
    Chen SC; Biswas C; Bartley R; Widmer F; Pantarat N; Obando D; Djordjevic JT; Ellis DH; Jolliffe KA; Sorrell TC
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3233-40. PubMed ID: 20530227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro susceptibility to fluconazole of fungal strains freshly isolated from child patients with deep-seated mycoses].
    Yamaguchi H; Uchida K
    Jpn J Antibiot; 1993 Aug; 46(8):647-53. PubMed ID: 8230734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.